deferoxamine has been researched along with Hemorrhagic Stroke in 1 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hemorrhagic Stroke: Stroke due to rupture of a weakened blood vessel in the brain (e.g., CEREBRAL HEMISPHERES; CEREBELLUM; SUBARACHNOID SPACE).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Van der Loo, LE | 1 |
| Aquarius, R | 1 |
| Teernstra, O | 1 |
| Klijn, K | 1 |
| Menovsky, T | 1 |
| van Dijk, JMC | 1 |
| Bartels, R | 1 |
| Boogaarts, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2a Exploratory Clinical Trial to Evaluate the Safety of Oral Deferiprone (14 Days) Including Its Effect on Decreasing the Content of Iron in Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) sIRB[NCT03754725] | Phase 1/Phase 2 | 66 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage[NCT02216513] | Early Phase 1 | 2 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to Principle Investigator is moving to another institution and plans to restart this proctocol in the new location.) | ||
| Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial[NCT02875262] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2022-12-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Hemorrhagic Stroke
| Article | Year |
|---|---|
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |